Helpdesk

Sales contact

Home > Resources > Emerging Biopharma & Biotech (EBP) – 5 key success factors for your clinical trials

Emerging Biopharma & Biotech (EBP) – 5 key success factors for your clinical trials

Last updated: July 3, 2024

With so much at stake, consider partnering with an eCOA and DCT expert!

Kayentis offers a unified platform featuring trustworthy services to ensure the success of electronic Clinical Outcome Assessment (eCOA) and decentralized clinical trials (DCT):

18+ years’ eCOA experience navigating diverse clinical trial challenges

A unified platform for decentralized clinical trials enhancing patient and site experience

Trusted partnership ensuring top-quality service delivery

Clinical and scientific experts empowering and supporting your teams

Therapeutic expertise addressing the unique needs of specific populations

Subscribe to our newsletter

Kayentis publishes its first ESG report, strengthening its commitment to...

Kayentis launches interactive eConsent solution to simplify and improve patient...

Better Raters,Smarter eCOA,Stronger Data

Strengthening Endpoint Reliability: An Interview with Estelle Haenel, Chief Medical...

Kayentis and RWS join forces to improve data confidence in...

What if eCOA could elevate your next rare disease trial?

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events